Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.

Kneller DW, Li H, Phillips G, Weiss KL, Zhang Q, Arnould MA, Jonsson CB, Surendranathan S, Parvathareddy J, Blakeley MP, Coates L, Louis JM, Bonnesen PV, Kovalevsky A

Open source

DOI: 10.1038/s41467-022-29915-z
Published: 2022 Apr 27
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-022-29915-z,
  title = {Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.},
  author = {Kneller DW and Li H and Phillips G and Weiss KL and Zhang Q and Arnould MA and Jonsson CB and Surendranathan S and Parvathareddy J and Blakeley MP and Coates L and Louis JM and Bonnesen PV and Kovalevsky A},
  year = {2022},
  journal = {Nature communications},
  doi = {10.1038/s41467-022-29915-z},
  url = {https://doi.org/10.1038/s41467-022-29915-z}
}

RIS

TY  - JOUR
TI  - Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
AU  - Kneller DW
AU  - Li H
AU  - Phillips G
AU  - Weiss KL
AU  - Zhang Q
AU  - Arnould MA
AU  - Jonsson CB
AU  - Surendranathan S
AU  - Parvathareddy J
AU  - Blakeley MP
AU  - Coates L
AU  - Louis JM
AU  - Bonnesen PV
AU  - Kovalevsky A
PY  - 2022
JO  - Nature communications
DO  - 10.1038/s41467-022-29915-z
UR  - https://doi.org/10.1038/s41467-022-29915-z
ER  -

APA

DW, K., H, L., G, P., KL, W., Q, Z., MA, A., CB, J., S, S., J, P., MP, B., L, C., JM, L., PV, B., & A, K. (2022). Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.. Nature communications. https://doi.org/10.1038/s41467-022-29915-z

Source records

pubmed · retrieved 2026-09-26T19:20:47.282Z